Categories: BioTechInformationMedtechTechnologyWebsite
Spica Therapeutics is a pioneering biotech company dedicated to transforming macrophage biology into breakthrough therapies for patients across multiple therapeutic areas. Leveraging its proprietary functional macrophage fingerprinting technology, Spica identifies and selectively targets disease-relevant macrophage sub
Investors 1
Funding Rounds 2
| Date | Series | Amount | Investors |
| 28.08.2025 | Grant | $1.17M | - |
| 04.06.2025 | Seed | $11.42M | - |
Mentions in press and media 4
| Date | Title | Description |
| 28.08.2025 | Spica Therapeutics secures € 1 Million VLAIO Grant to to advance macrophage-targeted therapies | Antwerp, Belgium - 27 August, 2025 - Spica Therapeutics, a pioneering biotech company focused on harnessing macrophage biology to develop transformative therapies across multiple disease areas, announced today that it has been awarded a €1.... |
| 04.06.2025 | Spica Therapeutics closes € 10 Million seed round to advance macrophage-targeted therapies | Antwerp, Belgium – 4th June, 2025 – Spica Therapeutics (“Spica” or “the Company”), a pioneering biotech company transforming macrophage biology into breakthrough therapies, announced the successful closing of a €10 million Seed financing ro... |
| 22.01.2025 | Bioqube Ventures Unveils Spica Therapeutics to Pioneer Macrophage-Subset Targeted Therapies | Brussels, Belgium, January 9, 2025 – Spica Therapeutics (“Spica”), a pioneering biotech company focused on macrophage biology, today announced its emergence from stealth mode, supported by Bioqube Ventures. Headquartered in Belgium, with a ... |
| - | Spica Therapeutics | “Spica Therapeutics is a pioneering biotech company dedicated to transforming macrophage biology into breakthrough therapies for patients across multiple therapeutic areas. Leveraging its proprietary functional macrophage fingerprinting tec... |
Reviews 0
